|Bid||246.01 x 800|
|Ask||247.00 x 900|
|Day's range||240.52 - 246.27|
|52-week range||129.21 - 275.87|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||36.68|
|Earnings date||26 Oct 2021|
|Forward dividend & yield||3.40 (1.57%)|
|Ex-dividend date||13 May 2021|
|1y target est||262.24|
These stocks are either immune to inflation or stand to benefit, the Mad Money host says.
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
Eli Lilly (LLY) closed at $243.75 in the latest trading session, marking a +1.07% move from the prior day.